Washington University in St. Louis

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

• Washington University School of Medicine

  St Louis, Missouri 63130

  1,081 trials

• Washington University

  St Louis, Missouri 63110

  232 trials

• Washington University in St. Louis

  St Louis, Missouri 63110

  127 trials

• Washington University St. Louis

  St Louis, Missouri 63110

  43 trials

• Washington University School of Medicine in St. Louis

  St Louis, Missouri 63110

  42 trials

• Washington University in St. Louis, School of Medicine

  St Louis, Missouri 63110

  16 trials

• Washington University Medical School

  St Louis, Missouri 63110

  12 trials

• Washington University School of Medicine - St. Louis

  St Louis, Missouri 63110

  12 trials

• Washington University in Saint Louis

  St Louis, Missouri 63110

  7 trials

• Washington University at St. Louis

  St Louis, Missouri 63110

  6 trials

• The Washington University

  St Louis, Missouri 63130

  5 trials

• Washington University of St. Louis

  St Louis, Missouri 63110

  5 trials

• Washington University School of Medicine, Division of Oncology

  St Louis, Missouri 63110

  3 trials

  • NCT05482971A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

  • NCT04285086Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

  • NCT04041310Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

• Washington University- Site Number : 840100

  St Louis, Missouri 63110

  3 trials

  • NCT00231400Pompe Disease Registry Protocol

    Contact: Pompe Registry HelpLine

  • NCT00196742Fabry Disease Registry & Pregnancy Sub-registry

    Contact: Trial Transparency

  • NCT00358943International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

    Contact: ICGG Gaucher Registry HelpLine

• Washington University Saint Louis

  St Louis, Missouri 63108

  2 trials

  • NCT07702032Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

  • NCT06514794A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

    Contact: Katie Stricker

• Washington University School of Medicine at St Louis

  St Louis, Missouri 63110

  2 trials

  • NCT03505710DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

  • NCT03526835A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

• Washington University School of Medicine, Department of Pediatrics, Division of Hematology/Oncology

  St Louis, Missouri 63110-1093

  2 trials

  • NCT05768386A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

  • NCT03370913Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)

• Washington University School of Medicine Dermatology

  St Louis, Missouri 63110

  2 trials

  • NCT05696392The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

  • NCT04517864PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

• Washington University School of Medicine Division of Medical Oncology

  St Louis, Missouri 63110

  2 trials

  • NCT04150965Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

  • NCT03732703Myeloma-Developing Regimens Using Genomics (MyDRUG)

• Washington University School of Medicine - Obstetrics & Gynecology

  St Louis, Missouri 63110

  2 trials

  • NCT04697628Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

  • NCT04579380Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

• Washington University School of Medicine (Site 0114)

  St Louis, Missouri 63110

  2 trials

  • NCT07489495A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

    Contact: Study Coordinator

  • NCT06788990FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

    Contact: Principal Investigator

• Washington University- Site Number : 8400076

  St Louis, Missouri 63110

  2 trials

  • NCT06141486Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

  • NCT06141473Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

• 8400840 - Washington University

  St Louis, Missouri 63110

  1 trial

  • NCT03473223Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

• Duplicate_Washington University of St. Louis /ID# 206972

  St Louis, Missouri 63141-6399

  1 trial

  • NCT03646604A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

• The Washington University School of Medicine

  St Louis, Missouri 63110

  1 trial

  • NCT03246529A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

• Washington University-Department of Medicine (Site 0044)

  St Louis, Missouri 63110

  1 trial

  • NCT05093933A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

• Washington University /ID# 107156

  St Louis, Missouri 63110

  1 trial

  • NCT01848561A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

• Washington University /ID# 257379

  St Louis, Missouri 63110

  1 trial

  • NCT06084481Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

• Washington University /ID# 262391

  St Louis, Missouri 63110

  1 trial

  • NCT06345339A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

• Washington University /ID# 266938

  St Louis, Missouri 63110

  1 trial

  • NCT06548542Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

• Washington University /ID# 266972

  St Louis, Missouri 63110

  1 trial

  • NCT06896916Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

• Washington University /ID# 267872

  St Louis, Missouri 63110

  1 trial

  • NCT06614192A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

• Washington University /ID# 275757

  St Louis, Missouri 63110

  1 trial

  • NCT06858813A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

• Washington University /ID# 280295

  St Louis, Missouri 63110

  1 trial

  • NCT07581002A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

• Washington University in St. Louis

  Louis, Missouri 63130

  1 trial

  • NCT07782021MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease

    Contact: Parakkal Deepak, MBBS, MS

• Washington University in St. Louis

  Washington, Missouri 63130

  1 trial

  • NCT05566769Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

    Contact: Robert T Naismith, MD

• Washington University in St. Louis - Center for Dermatologic and Cosmetic Surgery

  St Louis, Missouri 63141

  1 trial

  • NCT06585410Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

    Contact: Clinical Trials Administrator

• Washington University in St. Louis, Division of Oncology, Section of Bone Marrow Transplantation & Leukemia

  St Louis, Missouri 63110

  1 trial

  • NCT01081028Connect® MM- The Multiple Myeloma Disease Registry

• Washington University in St. Louis (Site 1384)

  St Louis, Missouri 63110

  1 trial

  • NCT04456699Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

• Washington University - Investigational Drug Service Pharmacy

  St Louis, Missouri 63110

  1 trial

  • NCT03485209Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

• Washington University - Mallinckrodt Institute of Radiology

  St Louis, Missouri 63110

  1 trial

  • NCT05711316The BD Liverty™ TIPS Stent Graft Study

• Washington University School of Medicine Gastroenterology

  St Louis, Missouri 63110

  1 trial

  • NCT04136002Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

• Washington University-School of Medicine /ID# 127575

  St Louis, Missouri 63110

  1 trial

  • NCT02163694A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

• Washington University-School of Medicine /ID# 149899

  St Louis, Missouri 63110

  1 trial

  • NCT02782663A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

• Washington University-School of Medicine /ID# 150537

  St Louis, Missouri 63110

  1 trial

  • NCT03006068A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

• Washington University-School of Medicine /ID# 153671

  St Louis, Missouri 63110

  1 trial

  • NCT02942290A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

• Washington University-School of Medicine /ID# 203217

  St Louis, Missouri 63110

  1 trial

  • NCT03539536Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

• Washington University-School of Medicine /ID# 207168

  St Louis, Missouri 63110

  1 trial

  • NCT03639194A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

• Washington University-School of Medicine /ID# 213453

  St Louis, Missouri 63110

  1 trial

  • NCT04189614An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

• Washington University-School of Medicine /ID# 214526

  St Louis, Missouri 63110

  1 trial

  • NCT04309474A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

• Washington University-School of Medicine /ID# 215325

  St Louis, Missouri 63110

  1 trial

  • NCT04295538Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

• Washington University-School of Medicine /ID# 215472

  St Louis, Missouri 63110

  1 trial

  • NCT04379050Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

• Washington University-School of Medicine /ID# 217723

  St Louis, Missouri 63110

  1 trial

  • NCT04750226Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

• Washington University-School of Medicine /ID# 221399

  St Louis, Missouri 63110

  1 trial

  • NCT03893955A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

• Washington University-School of Medicine /ID# 222651

  St Louis, Missouri 63110

  1 trial

  • NCT02899052Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

• Washington University-School of Medicine /ID# 225698

  St Louis, Missouri 63110

  1 trial

  • NCT04721015Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

• Washington University-School of Medicine /ID# 238681

  St Louis, Missouri 63110

  1 trial

  • NCT03933735A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

• Washington University-School of Medicine /ID# 240797

  St Louis, Missouri 63110

  1 trial

  • NCT05139602A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

• Washington University-School of Medicine /ID# 245452

  St Louis, Missouri 63110

  1 trial

  • NCT05411198Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

• Washington University-School of Medicine /ID# 246286

  St Louis, Missouri 63110

  1 trial

  • NCT05599984Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

• Washington University-School of Medicine /ID# 252698

  St Louis, Missouri 63110

  1 trial

  • NCT05822752Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

• Washington University-School of Medicine /ID# 255720

  St Louis, Missouri 63110

  1 trial

  • NCT06109272A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

• Washington University-School of Medicine /ID# 259684

  St Louis, Missouri 63110

  1 trial

  • NCT03821935Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

• Washington University-School of Medicine /ID# 262943

  St Louis, Missouri 63110

  1 trial

  • NCT06158958A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

• Washington University School of Medicine-Internal Medicine/Oncology (Site 0062)

  St Louis, Missouri 63110

  1 trial

  • NCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    Contact: Study Coordinator

• Washington University School of Medicine Neurology Clinical Unit

  St Louis, Missouri 63110

  1 trial

  • NCT06735248A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

    Contact: Moderna WeCare Team

• Washington University School of Medicine Obstetrics and Gynecology

  St Louis, Missouri 63110

  1 trial

  • NCT06161025A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

• Washington University School of Medicine-Obstetrics & Gynecology (Site 4146)

  St Louis, Missouri 63110

  1 trial

  • NCT06132958Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

• Washington University School of Medicine (Site 0024)

  St Louis, Missouri 63110

  1 trial

  • NCT07221474A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

    Contact: Study Coordinator

• Washington University School of Medicine (Site 0027)

  St Louis, Missouri 63110

  1 trial

  • NCT04662710Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

• Washington University School of Medicine (Site 0040)

  St Louis, Missouri 63110

  1 trial

  • NCT03615326Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

• Washington University School of Medicine (Site 0052)

  St Louis, Missouri 63110

  1 trial

  • NCT06824467A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

    Contact: Study Coordinator

• Washington University School of Medicine (Site 0060)

  St Louis, Missouri 63110

  1 trial

  • NCT04199104A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

• Washington University - School of Medicine (Site 0062)

  St Louis, Missouri 63110

  1 trial

  • NCT03740165Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

• Washington University School of Medicine (Site 0066)

  St Louis, Missouri 63110

  1 trial

  • NCT04732221A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

• Washington University School of Medicine (Site 0076)

  St Louis, Missouri 63110

  1 trial

  • NCT06312176A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    Contact: Study Coordinator

• Washington University School of Medicine (Site 0129)

  St Louis, Missouri 63110

  1 trial

  • NCT06052059A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

• Washington University School of Medicine (Site 0134)

  St Louis, Missouri 63110

  1 trial

  • NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

    Contact: Study Coordinator

• Washington University School of Medicine (Site 0240)

  St Louis, Missouri 63110

  1 trial

  • NCT04489888A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

• Washington University School of Medicine (Site 1022)

  St Louis, Missouri 63110

  1 trial

  • NCT04896008A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

• Washington University School of Medicine (Site 1500)

  St Louis, Missouri 63110

  1 trial

  • NCT04428151Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

• Washington University School of Medicine (Site 1779)

  St Louis, Missouri 63110

  1 trial

  • NCT03635567Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

• Washington University School of Medicine (Site 1800)

  St Louis, Missouri 63110

  1 trial

  • NCT03765918Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

• Washington University School of Medicine (Site 3279)

  St Louis, Missouri 63110

  1 trial

  • NCT07513376A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    Contact: Study Coordinator

• Washington University - School of Medicine (Site 5006)

  St Louis, Missouri 63110

  1 trial

  • NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    Contact: Study Coordinator

• Washington University School of Medicine (Site 5058)

  St Louis, Missouri 63110

  1 trial

  • NCT06430801A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

    Contact: Study Coordinator

• Washington University School of Medicine Site Number : 125

  St Louis, Missouri 63110

  1 trial

  • NCT05305989Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

• Washington University School of Medicine Site Number : 8400007

  St Louis, Missouri 63110

  1 trial

  • NCT06118099Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

• Washington University School of Medicine- Site Number : 8400035

  St Louis, Missouri 63110

  1 trial

  • NCT04751487Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

• Washington University School of Medicine- Site Number : 8400037

  St Louis, Missouri 63110

  1 trial

  • NCT06290141A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

• Washington University School of Medicine-Site Number: 8400075

  St Louis, Missouri 63110

  1 trial

  • NCT07184931An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

• Washington University School of Medicine - St. Louis /ID# 254506

  St Louis, Missouri 63130

  1 trial

  • NCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

• Washington University School of Medicine - St. Louis /ID# 256383

  St Louis, Missouri 63108

  1 trial

  • NCT05407636Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

• Washington University School of Medicine - St. Louis /ID# 268545

  St Louis, Missouri 63130

  1 trial

  • NCT06461897A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

• Washington University School of Medicine - St. Louis /ID# 268897

  St Louis, Missouri 63130

  1 trial

  • NCT05456685Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

• Washington University School of Medicine - St. Louis /ID# 269048

  St Louis, Missouri 63130

  1 trial

  • NCT05527184First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

• Washington University School of Public Health

  St Louis, Missouri 63110

  1 trial

  • NCT06470230RESPECT: (REsearching Stigma in PEdiatric Cancer Tool)

• Washington University School of St. Louis

  St Louis, Missouri 63110

  1 trial

  • NCT04756726Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

• Washington University (Site 0003)

  St Louis, Missouri 63110

  1 trial

  • NCT04241185Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

• Washington University (Site 0113)

  St Louis, Missouri 63110

  1 trial

  • NCT05446870Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

• Washington University (Site #: 71157)

  St Louis, Missouri 63130

  1 trial

  • NCT06476132Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

    Contact: Brigitte Mittler

• Washington University- Site Number : 150612

  St Louis, Missouri 63110

  1 trial

  • NCT00567073Pompe Pregnancy Sub-Registry

    Contact: Pompe Registry HelpLine

• Washington University- Site Number : 8400001

  St Louis, Missouri 63110

  1 trial

  • NCT05669989International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

• Washington University- Site Number : 8400007

  St Louis, Missouri 63110

  1 trial

  • NCT06356571A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

• Washington University- Site Number : 8400010

  St Louis, Missouri 63110

  1 trial

  • NCT07170917Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

• Washington University- Site Number : 8400025

  St Louis, Missouri 63110

  1 trial

  • NCT06557772A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

• Washington University- Site Number : 8400046

  St Louis, Missouri 63110

  1 trial

  • NCT06280391A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

• Washington University- Site Number : 8400144

  St Louis, Missouri 63110

  1 trial

  • NCT07190222Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

• Washington University- Site Number : 8402035

  St Louis, Missouri 63110

  1 trial

  • NCT06208306A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD

• Washington University - St. Louis (Site 900)

  St Louis, Missouri 63110

  1 trial

  • NCT04283669Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas